In this study, we used 5-aza as a positive control, and found that combination with 5-aza diminished EVO’s anti-lung cancer effects and the inhibition of NOTCH3 activation, suggesting that EVO may inhibit NOTCH3 signaling by activation of the DNMTs-induced NOTCH3 methylation. The gene discussed is NOTCH3; the disease is lung carcinoma.